4-1BBL AND IL-12 COMBINATION THERAPY FOR GLIOBLASTOMA

Thu, 09 Apr 2026 12:25:57 +0000
Intellectual Property

The USPTO published patent application US20260097096A1, a new intellectual property grant covering methods of treating glioblastoma using 4-1BBL administered via adeno-associated virus (AAV-F) in combination with recombinant IL-12 delivered by intratumoral injection. The patent names Koen Breyne, Xandra O. Breakefield, and Thorsten R. Mempel as inventors. Biotech and pharmaceutical companies developing cancer immunotherapies must monitor this IP landscape.